TY - JOUR
T1 - Treatment, outcomes, and adherence to medication regimens among dual Medicare-Medicaid–eligible adults with myocardial infarction
AU - Doll, Jacob A.
AU - Hellkamp, Anne S.
AU - Goyal, Abhinav
AU - Sutton, Nadia R.
AU - Peterson, Eric D.
AU - Wang, Tracy Y.
N1 - Funding Information:
Funding/Support: This project was supported by
Funding Information:
completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Dr Peterson reports grants and personal fees from Janssen and personal fees from Boehringer Ingelheim, Merck, Sanofi, Bayer, and Astra Zeneca outside the scope of the submitted work. Dr Wang reports research grant support from Eli Lilly, Daiichi Sankyo, Astra Zeneca, Bristol Myers Squibb, Boston Scientific, Gilead, Glaxo Smith Kline, and Regeneron; consulting services from Eli Lilly, Astra Zeneca, and Premier. No other disclosures are reported.
Funding Information:
All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Dr Peterson reports grants and personal fees from Janssen and personal fees from Boehringer Ingelheim, Merck, Sanofi, Bayer, and Astra Zeneca outside the scope of the submitted work. Dr Wang reports research grant support from Eli Lilly, Daiichi Sankyo, Astra Zeneca, Bristol Myers Squibb, Boston Scientific, Gilead, Glaxo Smith Kline, and Regeneron; consulting services from Eli Lilly, Astra Zeneca, and Premier. No other disclosures are reported. This project was supported by grant number U19HS021092 from the Agency for Healthcare Research and Quality (AHRQ) (Dr Doll).
Publisher Copyright:
Copyright 2016 American Medical Association. All rights reserved.
PY - 2016/10
Y1 - 2016/10
N2 - IMPORTANCE: Patients with dual Medicare-Medicaid eligibility have a higher burden of chronic disease conditions and increased health care utilization compared with patients with Medicare coverage alone, but the treatment patterns and outcomes of dual-eligible patients with myocardial infarction (MI) are unknown. OBJECTIVE: To examine the association of dual-eligible status with clinical outcomes and adherence to medication regimens (hereinafter “medication adherence”) among older adults after MI. DESIGN, SETTING, AND PARTICIPANTS: In this retrospective study conducted from February 2015 to April 2016, we linked patients 65 years or older enrolled in a national myocardial infarction registry (the Acute Coronary Treatment Intervention Outcomes Network Registry–Get With the Guidelines [ACTION Registry-GWTG]) from July 1, 2007, to December 31, 2009, to Medicare claims data to obtain 1-year follow-up and medication adherence data. The ACTION Registry-GWTG is the largest quality-improvement registry of patients with MI in the United States. Included patients were all 65 years or older; had Medicare Parts A, B, and D; presented with MI; and survived to hospital discharge. EXPOSURES Dual Medicare and Medicaid eligibility. MAIN OUTCOMES AND MEASURES: Death, readmission, major adverse cardiovascular events (death, recurrent MI, stroke), and medication adherence at 1 year. RESULTS: Of 17 419 Medicare patients discharged alive after MI, 4674 (27%) were dual eligible. Dual-eligible patients were more likely to be female (64% vs 49%) and nonwhite (29% vs 6%), with a higher prevalence of comorbid conditions and more frequent presentation with non-ST elevation MI (non-STEMI) (75% vs 69%). Dual-eligible patients were less likely to receive primary percutaneous coronary intervention for STEMI (77% vs 81%), revascularization for non-STEMI (58% vs 65%), and prescription of secondary prevention medications at discharge. After multivariable adjustment, dual eligibility status was associated with a higher risk of readmission at 30 days (hazard ratio [HR], 1.16; 95% CI, 1.06-1.26), death at 1 year (HR, 1.24; 95% CI, 1.14-1.36), and major adverse cardiac events at 1 year (HR, 1.21; 95% CI, 1.12-1.31). Dual-eligible patients had higher 1-year adherence to medications prescribed at discharge (HR, 1.55; 95% CI, 1.39-1.74) than Medicare-only patients. CONCLUSIONS AND RELEVANCE: Compared with Medicare-only patients, older adults with dual Medicare-Medicaid eligibility presenting with MI have superior rates of medication adherence but higher rates of postdischarge readmission and adverse cardiovascular outcomes.
AB - IMPORTANCE: Patients with dual Medicare-Medicaid eligibility have a higher burden of chronic disease conditions and increased health care utilization compared with patients with Medicare coverage alone, but the treatment patterns and outcomes of dual-eligible patients with myocardial infarction (MI) are unknown. OBJECTIVE: To examine the association of dual-eligible status with clinical outcomes and adherence to medication regimens (hereinafter “medication adherence”) among older adults after MI. DESIGN, SETTING, AND PARTICIPANTS: In this retrospective study conducted from February 2015 to April 2016, we linked patients 65 years or older enrolled in a national myocardial infarction registry (the Acute Coronary Treatment Intervention Outcomes Network Registry–Get With the Guidelines [ACTION Registry-GWTG]) from July 1, 2007, to December 31, 2009, to Medicare claims data to obtain 1-year follow-up and medication adherence data. The ACTION Registry-GWTG is the largest quality-improvement registry of patients with MI in the United States. Included patients were all 65 years or older; had Medicare Parts A, B, and D; presented with MI; and survived to hospital discharge. EXPOSURES Dual Medicare and Medicaid eligibility. MAIN OUTCOMES AND MEASURES: Death, readmission, major adverse cardiovascular events (death, recurrent MI, stroke), and medication adherence at 1 year. RESULTS: Of 17 419 Medicare patients discharged alive after MI, 4674 (27%) were dual eligible. Dual-eligible patients were more likely to be female (64% vs 49%) and nonwhite (29% vs 6%), with a higher prevalence of comorbid conditions and more frequent presentation with non-ST elevation MI (non-STEMI) (75% vs 69%). Dual-eligible patients were less likely to receive primary percutaneous coronary intervention for STEMI (77% vs 81%), revascularization for non-STEMI (58% vs 65%), and prescription of secondary prevention medications at discharge. After multivariable adjustment, dual eligibility status was associated with a higher risk of readmission at 30 days (hazard ratio [HR], 1.16; 95% CI, 1.06-1.26), death at 1 year (HR, 1.24; 95% CI, 1.14-1.36), and major adverse cardiac events at 1 year (HR, 1.21; 95% CI, 1.12-1.31). Dual-eligible patients had higher 1-year adherence to medications prescribed at discharge (HR, 1.55; 95% CI, 1.39-1.74) than Medicare-only patients. CONCLUSIONS AND RELEVANCE: Compared with Medicare-only patients, older adults with dual Medicare-Medicaid eligibility presenting with MI have superior rates of medication adherence but higher rates of postdischarge readmission and adverse cardiovascular outcomes.
UR - http://www.scopus.com/inward/record.url?scp=85026806734&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85026806734&partnerID=8YFLogxK
U2 - 10.1001/jamacardio.2016.2724
DO - 10.1001/jamacardio.2016.2724
M3 - Article
C2 - 27541822
AN - SCOPUS:85026806734
SN - 2380-6583
VL - 1
SP - 787
EP - 794
JO - JAMA Cardiology
JF - JAMA Cardiology
IS - 7
ER -